Search | IOVS | ARVO Journals

View

Showing 1 – 15 of 15

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Model development of VEGF challenge in miniature swine

Meredith Weksler; Alan McDougal; Tyler Pegoraro; Stuart Williams; Mitchell A. deLong; Casey Kopczynski; David Hollander; Jeffrey C. White

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1312 – F0146. doi:

ARVO Annual Meeting Abstract June 2022

ROCK’Sters, a novel compound class combining Rho kinase inhibition with corticosteroid anti-inflammatory activity for the treatment of ocular inflammation

Jill M. Sturdivant; Curtis Kelly; Daphne Clancy; Natalie Girouard; Maria Ina; Qing Wang; D'Quan Cutno; Stuart Williams; Mitchell A. deLong; Casey Kopczynski; David Hollander; Jeffrey C. White

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2111 – F0127. doi:

ARVO Annual Meeting Abstract June 2021

The Synthesis and Testing of Rho Kinase Inhibitors Reversibly Coupled to Corticosteroids for the Treatment of Ocular Inflammatory Diseases

Mitchell A. deLong; Curtis Kelly; Karen Crews; Jill M. Sturdivant; Angie Glendenning; Briana Foley; Daphne Clancy; Monica Germann; Jeff White

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):721. doi:

ARVO Annual Meeting Abstract June 2021

Novel corticosteroid class reduces inflammation and lowers IOP in animal models

Kevin Carbajal; Maria V. Zaretskaia; Cyndi L. Lichorowic; Jill M. Sturdivant; Meredith Weksler; Alan McDougal; Cheng-Wen Lin; Mitchell A. deLong; Casey Kopczynski; David A. Hollander; Jeff White

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1302. doi:

ARVO Annual Meeting Abstract June 2021

Ocular pharmacokinetics of a novel class of corticosteroids with ROCK inhibitory activity and potential for reduced steroid-associated risks

Maria V. Zaretskaia; Kevin Carbajal; Cyndi L. Lichorowic; Jill M. Sturdivant; Monica Germann; Christopher Romeo; Karen Crews; Angie Glendenning; Meredith Weksler; Alan McDougal; Mitchell A. deLong; Cheng-Wen Lin; Casey Kopczynski; David A. Hollander; Jeff White

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1292. doi:

ARVO Annual Meeting Abstract June 2020

A novel corticosteroid with ROCK inhibitory activity can reduce ocular inflammation and lower IOP in animal models

Kevin Carbajal; Maria V. Zaretskaia; Cyndi Lichorowic; Jill M. Sturdivant; Eric C Carlson; Monica Germann; Karen Crews; Meredith Weksler; Alan McDougal; Mitchell A. deLong; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2953. doi:

ARVO Annual Meeting Abstract June 2020

Novel corticosteroids with inhibitory activity against ROCK reach target ocular tissues and reduce inflammation in EIU

Maria V Zaretskaia; Kevin Carbajal; Cyndi Lichorowic; Jill M. Sturdivant; Eric C Carlson; Monica Germann; Karen Crews; Meredith Weksler; Alan McDougal; Mitchell A. deLong; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2983. doi:

ARVO Annual Meeting Abstract June 2020

Small-molecule JAK/IKK Kinase Inhibitors and JAK/ROCK/IKK Inhibitors for Treatment of Posterior Segment Disease via a Sustained Release PEA Bioerodible Implant.

Mitchell A. deLong; Briana Foley; Kyle Vick; Daphne Clancy; Steve Miller; Curtis Kelly; Jill M. Sturdivant; Cyndi Lichorowic; Cheng-Wen Lin; Casey Kopczynski

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4922. doi:

ARVO Annual Meeting Abstract July 2019

Anti-inflammatory Activity of a New Class of JAK/ROCK Inhibitors for Posterior Segment Disease

Mitchell A. deLong; Kyle Vick; jill Sturdivant; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5381. doi:

ARVO Annual Meeting Abstract July 2019

Ocular Pharmacokinetics of a Novel Class of Selective Multi-Kinase Inhibitors with Anti-Inflammatory Potential

Kevin Carbajal; Karen Crews; Kyle Vick; Briana E Foley; Jindong Ding; Angie Glendenning; Meredith Weksler; Cynthia L Lichorowic; Jill Sturdivant; Mitchell A. deLong; Eric C Carlson; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):250. doi:

ARVO Annual Meeting Abstract July 2018

Effect of Ring Size on the Suitability of a New Class of Rho Kinase Compounds for Posterior Segment Disease

Mitchell A deLong; Jill Sturdivant; Cynthia Lichorowic; Cheng-Wen Lin; Casey Kopczynski

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):217. doi:

ARVO Annual Meeting Abstract July 2018

Sustained Release, Biodegradable PEA Implants for Intravitreal Delivery of the ROCK/PKC Inhibitor AR-13503

Angela Glendenning; Karen Crews; Jill Sturdivant; Mitchell A deLong; Casey Kopczynski; Cheng-Wen Lin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5672. doi:

ARVO Annual Meeting Abstract June 2017

Discovery and Preliminary SAR of a New Class of Rho Kinase Compounds for the Treatment of Eye Diseases

Mitchell A deLong; Jill Sturdivant; Cynthia Lichorowic; Cheng-Wen Lin; Casey Kopczynski

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4610. doi:

ARVO Annual Meeting Abstract September 2016

Effectiveness of AR-13154 monotherapy and combination therapy in animal models of wet age-related macular degeneration and proliferative diabetic retinopathy

Cheng-Wen Lin; Jill M Sturdivant; Mitchell A deLong; Casey Kopczynski

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):287. doi:

ARVO Annual Meeting Abstract March 2012

Discovery and SAR of a Class of Ocularly-active Compounds Displaying a Dual Mechanism of Activity for the Treatment of Glaucoma

Mitchell A. deLong; Jeff Yingling; Cheng-Wen Lin; Bryan Sherman; Jill Sturdivant; Geoff Heintzelman; Carmen Lathem; Tom van Haarlem; Casey Kopczynski

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):3867. doi:

Advertisement